Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19

Ladan Abbasian,Negar Toroghi,Hamid Rahmani,Hossein Khalili,Malihe Hasannezhad,Fereshteh Ghiasvand,Sirous Jafari,Mohammadreza Salehi,Faeze Salahshour, Mahsa Azadbakhsh Kanaf Gorabi, Fateme Alizade,Sara Ghaderkhani, Maryam Nakhostin

International Immunopharmacology（2022）

引用 1|浏览3

暂无评分

摘要

•Clinical response occurred faster in the tocilizumab than methylprednisolone group.•Improvement rate of SpO2 and CRP were comparable between the groups.•28-day mortality was not different among patents in the groups.•More patients in the tocilizumab group experienced sleep disturbances.•Methylprednisolone may be an alternative in the treatment of severe COVID-19.

查看译文

关键词

Methylprednisolone,Tocilizumab,COVID,Dexamethasone

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要